Brokerages Set Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Price Target at $17.33

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) has been given an average recommendation of “Buy” by the six research firms that are presently covering the company, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a buy recommendation. The average 1-year price target among brokerages that have covered the stock in the last year is $17.33.

A number of equities research analysts recently commented on the company. Chardan Capital reaffirmed a “buy” rating and set a $18.00 price objective on shares of Tenaya Therapeutics in a research note on Wednesday, December 18th. HC Wainwright reissued a “buy” rating and issued a $18.00 target price on shares of Tenaya Therapeutics in a research note on Monday, February 3rd.

Institutional Trading of Tenaya Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the stock. abrdn plc bought a new stake in Tenaya Therapeutics in the third quarter valued at approximately $1,063,000. FMR LLC grew its position in shares of Tenaya Therapeutics by 1.9% in the third quarter. FMR LLC now owns 1,345,938 shares of the company’s stock valued at $2,598,000 after purchasing an additional 25,503 shares during the last quarter. Walleye Capital LLC acquired a new position in shares of Tenaya Therapeutics in the third quarter valued at approximately $134,000. Jacobs Levy Equity Management Inc. grew its position in shares of Tenaya Therapeutics by 204.4% in the third quarter. Jacobs Levy Equity Management Inc. now owns 337,265 shares of the company’s stock valued at $651,000 after purchasing an additional 226,466 shares during the last quarter. Finally, State Street Corp grew its position in shares of Tenaya Therapeutics by 0.9% in the third quarter. State Street Corp now owns 1,058,898 shares of the company’s stock valued at $2,044,000 after purchasing an additional 9,506 shares during the last quarter. Institutional investors own 90.54% of the company’s stock.

Tenaya Therapeutics Stock Up 3.3 %

Shares of Tenaya Therapeutics stock opened at $0.47 on Tuesday. Tenaya Therapeutics has a 12 month low of $0.39 and a 12 month high of $6.78. The business has a fifty day simple moving average of $1.17 and a 200 day simple moving average of $1.92. The stock has a market cap of $37.23 million, a PE ratio of -0.33 and a beta of 2.84.

Tenaya Therapeutics Company Profile

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.